Cargando…

Retrograde inferior vena caval perfusion for total aortic arch replacement surgery: a randomized pilot study

OBJECTIVES: Antegrade cerebral perfusion (ACP) under moderate hypothermic circulatory arrest is used during total aortic arch replacement surgery (TARS) in patients with acute type A aortic dissection, but it is associated with high mortality and morbidity. We hypothesized that combining ACP with re...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jing, Qin, Zhen, Liu, Xinhao, Xiong, Jiyue, Wu, Zhong, Guo, Yingqiang, Kang, Deying, Du, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056667/
https://www.ncbi.nlm.nih.gov/pubmed/33879045
http://dx.doi.org/10.1186/s12872-021-02002-9
_version_ 1783680694211313664
author Lin, Jing
Qin, Zhen
Liu, Xinhao
Xiong, Jiyue
Wu, Zhong
Guo, Yingqiang
Kang, Deying
Du, Lei
author_facet Lin, Jing
Qin, Zhen
Liu, Xinhao
Xiong, Jiyue
Wu, Zhong
Guo, Yingqiang
Kang, Deying
Du, Lei
author_sort Lin, Jing
collection PubMed
description OBJECTIVES: Antegrade cerebral perfusion (ACP) under moderate hypothermic circulatory arrest is used during total aortic arch replacement surgery (TARS) in patients with acute type A aortic dissection, but it is associated with high mortality and morbidity. We hypothesized that combining ACP with retrograde inferior vena caval perfusion (RIVP) improves outcomes. METHODS: This pilot study was prospective, randomized, controlled and assessor-blinded. Patients scheduled for TARS were randomly treated with either ACP or RIVP + ACP. The primary outcome was a composite of mortality and major complications including paraplegia, postoperative renal failure, severe liver dysfunction, and gastrointestinal complications. Secondary outcomes included neurological complications, length of intubation and requirement of blood products. RESULTS: A total of 76 patients were recruited (n = 38 per group). Primary outcome occurred in 23 patients (61%) in the ACP group and 16 (42%) in the RIVP + ACP group (OR: 0.60, 95% CI: 0.21–1.62; p = 0.31). There was a lower incidence of transient neurological deficits in the RIVP + ACP group (26% vs. 58%, OR: 0.26; 95% CI: 0.10–0.67,p = 0.006;). The RIVP + ACP group underwent shorter intubation (25 vs 47 h, p = 0.022) and required fewer blood products (red cells, 3.8 units vs 6.5 units, p = 0.047; platelet: 2.0 units vs 2.0 units, p = 0.023) compared with the ACP group. CONCLUSIONS: RIVP + ACP may be associated with lower incidence of transient neurological deficits, shorter intubation and less blood transfusion requirement than ACP alone during TARS. Multi-center, randomized trials with larger samples are required to determine whether RIVP + ACP is associated with lower rates of mortality and major complications. Trial registration: Pilot study of a RCT registered in clinicaltrials.gov (NCT03607786), Registered 30 July, 2018—Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03607786. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-021-02002-9.
format Online
Article
Text
id pubmed-8056667
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80566672021-04-20 Retrograde inferior vena caval perfusion for total aortic arch replacement surgery: a randomized pilot study Lin, Jing Qin, Zhen Liu, Xinhao Xiong, Jiyue Wu, Zhong Guo, Yingqiang Kang, Deying Du, Lei BMC Cardiovasc Disord Research Article OBJECTIVES: Antegrade cerebral perfusion (ACP) under moderate hypothermic circulatory arrest is used during total aortic arch replacement surgery (TARS) in patients with acute type A aortic dissection, but it is associated with high mortality and morbidity. We hypothesized that combining ACP with retrograde inferior vena caval perfusion (RIVP) improves outcomes. METHODS: This pilot study was prospective, randomized, controlled and assessor-blinded. Patients scheduled for TARS were randomly treated with either ACP or RIVP + ACP. The primary outcome was a composite of mortality and major complications including paraplegia, postoperative renal failure, severe liver dysfunction, and gastrointestinal complications. Secondary outcomes included neurological complications, length of intubation and requirement of blood products. RESULTS: A total of 76 patients were recruited (n = 38 per group). Primary outcome occurred in 23 patients (61%) in the ACP group and 16 (42%) in the RIVP + ACP group (OR: 0.60, 95% CI: 0.21–1.62; p = 0.31). There was a lower incidence of transient neurological deficits in the RIVP + ACP group (26% vs. 58%, OR: 0.26; 95% CI: 0.10–0.67,p = 0.006;). The RIVP + ACP group underwent shorter intubation (25 vs 47 h, p = 0.022) and required fewer blood products (red cells, 3.8 units vs 6.5 units, p = 0.047; platelet: 2.0 units vs 2.0 units, p = 0.023) compared with the ACP group. CONCLUSIONS: RIVP + ACP may be associated with lower incidence of transient neurological deficits, shorter intubation and less blood transfusion requirement than ACP alone during TARS. Multi-center, randomized trials with larger samples are required to determine whether RIVP + ACP is associated with lower rates of mortality and major complications. Trial registration: Pilot study of a RCT registered in clinicaltrials.gov (NCT03607786), Registered 30 July, 2018—Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03607786. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-021-02002-9. BioMed Central 2021-04-20 /pmc/articles/PMC8056667/ /pubmed/33879045 http://dx.doi.org/10.1186/s12872-021-02002-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Lin, Jing
Qin, Zhen
Liu, Xinhao
Xiong, Jiyue
Wu, Zhong
Guo, Yingqiang
Kang, Deying
Du, Lei
Retrograde inferior vena caval perfusion for total aortic arch replacement surgery: a randomized pilot study
title Retrograde inferior vena caval perfusion for total aortic arch replacement surgery: a randomized pilot study
title_full Retrograde inferior vena caval perfusion for total aortic arch replacement surgery: a randomized pilot study
title_fullStr Retrograde inferior vena caval perfusion for total aortic arch replacement surgery: a randomized pilot study
title_full_unstemmed Retrograde inferior vena caval perfusion for total aortic arch replacement surgery: a randomized pilot study
title_short Retrograde inferior vena caval perfusion for total aortic arch replacement surgery: a randomized pilot study
title_sort retrograde inferior vena caval perfusion for total aortic arch replacement surgery: a randomized pilot study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056667/
https://www.ncbi.nlm.nih.gov/pubmed/33879045
http://dx.doi.org/10.1186/s12872-021-02002-9
work_keys_str_mv AT linjing retrogradeinferiorvenacavalperfusionfortotalaorticarchreplacementsurgeryarandomizedpilotstudy
AT qinzhen retrogradeinferiorvenacavalperfusionfortotalaorticarchreplacementsurgeryarandomizedpilotstudy
AT liuxinhao retrogradeinferiorvenacavalperfusionfortotalaorticarchreplacementsurgeryarandomizedpilotstudy
AT xiongjiyue retrogradeinferiorvenacavalperfusionfortotalaorticarchreplacementsurgeryarandomizedpilotstudy
AT wuzhong retrogradeinferiorvenacavalperfusionfortotalaorticarchreplacementsurgeryarandomizedpilotstudy
AT guoyingqiang retrogradeinferiorvenacavalperfusionfortotalaorticarchreplacementsurgeryarandomizedpilotstudy
AT kangdeying retrogradeinferiorvenacavalperfusionfortotalaorticarchreplacementsurgeryarandomizedpilotstudy
AT dulei retrogradeinferiorvenacavalperfusionfortotalaorticarchreplacementsurgeryarandomizedpilotstudy